Arvinas to Present at Upcoming Investor Conferences
ByAinvest
Friday, Aug 29, 2025 7:03 am ET1min read
ARVN--
Arvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform aims to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers.
References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141410/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://www.stocktitan.net/news/ARVN/arvinas-to-participate-in-upcoming-investor-n1atndee88b7.html
Arvinas, a clinical-stage biotechnology company, announced that management will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference. The events will be webcast live on the company's website. Arvinas is developing protein degradation therapies using its PROTAC platform for diseases such as breast cancer, non-Hodgkin lymphoma, and neurodegenerative disorders.
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, announced that management will participate in fireside chats at two upcoming investor conferences. The events, scheduled for September 4 and 5, include the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference, respectively. Live audio webcasts of both presentations will be accessible through the company's website under the "Events and Presentations" section of the Investors and Media page.Arvinas is dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform aims to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers.
References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141410/0/en/Arvinas-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://www.stocktitan.net/news/ARVN/arvinas-to-participate-in-upcoming-investor-n1atndee88b7.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet